24 May 2020

Multiple Job Openings at S Kant Healthcare Ltd | M.Sc, M.Pharm, B.Pharm

24 May 2020
Vacancy for M.Pharm, B.Pharm, M.Sc in Production, QA at Macleods Pharmaceuticals

Macleods with its experience spanning more than two decades has emerged as a force to reckon with in global pharmaceutical market. With an asset of more than 10,000 professionally qualified employees across the globe, Macleods a multiple location organization, is based out of Mumbai, India.

24 May 2020
Career opportunities for M.Pharm, M.Sc as Quality Control Head at Syngene

Syngene International is one of India’s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery chain: early stage discovery, process development, cGMP manufacturing and formulation development both in the small molecule and novel biologics area. Based in Bangalore, Karnataka, the Company is situated in a 90 acre Special Economic Zone with over 100000 sq. mt of built up facilities.

Post : HEAD QC - BIOLOGICS

24 May 2020
Career for Research Scientist at Himalaya Drug Company

Every year, 300 million Himalaya products enter the homes of consumers around the world. With a range of over 300 healthcare and personal care products including brands like Liv.52, Cystone, and Bonnisan, we touch the lives of millions of customers worldwide, giving them products that help them lead healthier, enriched lives. Himalaya’s story began way back in 1930. A curious young man riding through the forests of Burma saw restless elephants being fed the root of a plant, Rauwolfia serpentina, which helped pacify them.

Post : Research Scientist / Senior Research Scientist

24 May 2020
Work in Quality Control, IPQA Department at Gland Pharma

Gland Pharma Limited manufactures and markets small volume parenteral solutions. The Company offers injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions, as well as generic products. Gland Pharma conducts its business worldwide.

23 May 2020
Recruitment for Pharmacists(11 posts) under NHM | Government Jobs

Office of the Deputy Director of National Health Mission, Aarogya Seva, Nashik Board, Nashik Recruitment Process District Ahmednagar for the recruitment process for the posts in the district of Ahmednagar coming under Nashik Circle under National Health Mission, as shown in below.  Applications are being invited by mail.

Post : Pharmacist

23 May 2020
Pharmacist Hero Vol 9

PharmaTutor facilitating these Pharmacy warriors who are contributing against fight of COVID-19. This is Volume 9. We shall keep posting list of more Pharmacist Heroes.

Any pharmacist from industry, academics, researcher or community pharmacist who contributing actively for fight aganist COVID-19 can send their details.

 

A webinar on ‘Medical Devices and API sector: Challenges & Emerging Opportunities’ was held on 22nd May, 2020 at 11.30 am for business and trade collaboration between India and Japan in the post COVID-19 scenario. The webinar was organized by the Embassy of India, Tokyo in partnership with the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India.

Mr. Sanjay Kumar Verma, Ambassador of India to Japan shared his valuable thoughts on the golden opportunity for India and Japan to further boost their relationship in the context of the ongoing COVID-19 crisis. Dr. P. D. Vaghela, Secretary, Pharmaceuticals presented the sectoral view and the investment opportunities in the pharmaceutical and medical device industry in India. He also presented various initiatives taken by the Government of India to promote trade and business in the country. Mr. Navdeep Rinwa, Joint Secretary, Pharmaceuticals explained the Department’s schemes to promote manufacturing of bulk drugs and medical devices viz. Production Linked Incentive schemes and Promotion of Bulk Drug/Medical Devices Parks and requested the delegates to avail benefits of the schemes.

Pharmaceutical Traders Association and Japan Federation of Medical Devices Associations deliberated on the Post COVID-19 challenges & opportunities for Pharmaceutical & Medical Device sectors and its impact on the global supply chain and suggested that cooperation between the two countries can contribute to stabilize the supply-chain of especially APIs and Medical Devices. Representative of JETRO Chennai also shared insights on challenges and emerging opportunities in API sector and Medical Devices.


?Ms. Mona K C Khandhar, Minister (Economic & Commerce), EoI, Tokyo mentioned about the resilience and strength of the Indian economy and detailed on the stimulus & reform packages announced by the Government of India to address the COVID-19 crisis and to improve the investment environment. The advantages of Indian economy, FDI ecosystem & Japan specific facilitation were also mentioned.

Representatives of Japanese subsidiaries Nipro India Corp and Eisai Pharmaceuticals India Pvt Ltd shared a detailed presentation and their experience about ‘Make in India’ program.


Representatives of major Indian Pharmaceutical and Medical Device Associations presented the future growth opportunities and way forward for Pharmaceutical and Medical Device industry in India.

?Representatives of State Governments of Gujarat, Telangana, Himachal Pradesh and Goa offered finer details of the investment opportunities in their respective States including package for incentives and taxation benefits, ease of doing business initiatives, land availability, infrastructural facilities, regulatory framework and invited Japanese companies for investing in their respective States.

?Representatives of Andhra Pradesh MedTech Zone, Wockhardt, Sun Pharma, Panacea Biotec and other large number of Japanese companies also participated in the webinar as part of G2B and B2B networking.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

The Union Minister of Health & Family Welfare Dr. Harsh Vardhan has been elected as Chair of the Executive Board of World Health Organization for the year 2020-21. This took place today during the 147th session of the Executive Board, in a meeting that was virtually held.Hehas replacedDr Hiroki Nakatani of Japan.

22 May 2020
Recruitment for Pharmacists (07 posts) at District Integrated Health & Family Welfare Society

District Integrated Health and Family Welfare Society Ratnagiri Candidates on behalf of District Integrated Health and Family Welfare Society apply for the following post on net contract basis in the prescribed form by post or in person at District Health Officer's Office, Health Department, ZP Ratnagiri.

Post : Pharmacist

22 May 2020
Research Jobs at Indian Institute of Technology

Indian Institute of Technology Delhi is one of the 23 IITs created to be Centres of Excellence for training, research and development in science, engineering and technology in India.  Established as College of Engineering in 1961, the Institute was later declared as an Institution of National Importance under the “Institutes of Technology (Amendment) Act, 1963” and was renamed as “Indian Institute of Technology Delhi”.

22 May 2020
Alkem Laboratories Limited looking for Medical Advisor | M.Pharm, Ph.D

Alkem Laboratories Limited, established in 1973, a top five leading Indian Pharmaceutical Company with global operations, engaged in the development, manufacturing and sale of Pharmaceutical and Ncutraccutical Products, which are marketed in India and 55 countries internationally, primarily in the United States. We are looking for Energetic. Enthusiastic & Motivated personnel for our formulation units at Sikkim.

Post : Medical Advisor

22 May 2020
Require Associate Director at AstraZeneca

AstraZeneca is an exciting global, innovation-driven biopharmaceutical company. We’re inspired by what science can do. Driven by the desire to meet unmet patient needs in our core therapeutic areas. Bold in our thinking. Proactive in pursuing discoveries beyond imagination.

Post : Associate Director I - Product Regulatory Affairs

22 May 2020
Regulatory Specialist require at GSK Limited

GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 5000+ people. Globally, we are a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders.

Post : Regulatory Specialist, Variations – Senior

Indian researchers and authorities have prioritized to reduce dependence on other countries by developing and validating indigenous diagnostic assays for COVID-19 testing. A total of 11 RT-PCR-based indigenous assays were validated and recommended for the testing of COVID-19. This has been revealed by the Indian Council of Medical Research (ICMR).

Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application (“ANDA”) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (U.S. FDA) with a Competitive Generic Therapy (“CGT”) designation. Cipla is the “first approved applicant” for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product. This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.

AMAG Pharmaceuticals, Inc announced it has completed the sale of its rights to Intrarosa (prasterone) to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in womens health and menopause-related conditions, for up to USD 125 million, including upfront fixed consideration of USD 20 million and contingent, sales-based milestone payments of up to USD105 million.

"As mentioned in our first quarter earnings release, the sale of Intrarosa is an important step in our strategic evolution,” said Scott Myers AMAG’s president and chief executive officer. “We were impressed with Millicent’s commercial capabilities and dedication to women’s healthcare and we are pleased to transition this important therapy into their portfolio. We remain focused on maximizing Feraheme’s value, maintaining patient access to Makena and developing innovative therapies, while managing expenses to help further our goal of achieving profitability in 2020.”

In addition to the upfront consideration of USD 20 million, AMAG will be entitled to certain sales milestone payments, which include USD 25 million the first time Intrarosa net sales exceed USD 65 million during any consecutive 12-month period, a second sales milestone payment of USD 35 million the first time Intrarosa net sales exceed USD 115 million during any consecutive 12-month period, and a third milestone payment of USD 45 million the first time Intrarosa net sales exceed SUD 175 million during any consecutive 12-month period.

The sale of Intrarosa is consistent with AMAG’s previously announced strategic decision to divest its women’s health assets. AMAG has agreed to provide certain transitional services to Millicent Pharma for a limited period of time while Intrarosa is operationally separated from AMAG. AMAG remains committed to the divestiture of Vyleesi and associated expense reductions as previously announced.


<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

Scientists have identified specific compounds from the Brazilian peppertree -- a weedy, invasive shrub in Florida -- that reduce the virulence of antibiotic-resistant staph bacteria. Scientific Reports published the research, demonstrating that triterpenoid acids in the red berries of the plant "disarm" dangerous staph bacteria by blocking its ability to produce toxins.

22 May 2020
Troikaa Pharmaceuticals receives US patent for Dynapar QPS

Ahmedabad based Troikaa Pharmaceuticals Ltd. has received patent for its novel non-aqueous Topical Solution of Diclofenac by the U.S. Patent Office which is marketed under the brand name Dynapar QPS.

21 May 2020
Recruitment for Pharmacists under Health and Family Welfare Department

Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighbouring parts of Karnataka and Tamilnadu states.

Subscribe to